PredictImmune initiates its PRECIOUS study to validate PredictSURE IBD
Category: #healthcare  By Mateen Dalal  Date: 2019-11-08
  • share
  • Twitter
  • Facebook
  • LinkedIn

PredictImmune initiates its PRECIOUS study to validate PredictSURE IBD

The study would deliver crucial data that could help PredictImmune validate PredictSURE IBDTM in diverse patient populations.
 

PredictImmune has made its name by developing advanced tools for guiding treatment alternatives for diseases that are caused due to immune mediated diseases, like inflammatory bowel disease. Recently, the company made headlines when it announced the commencement of the PRECIOUS (Predicting Crohn’s and Colitis Outcomes in the United States) trial along with Crohn’s & Colitis Foundation.

For the record, the PRECIOUS trial is an observational, multi-center study of patients who suffer from active ulcerative colitis or Crohn’s disease and who are not treated with immunomodulators, biologics or systemic steroids.

Reports cite that the study would enroll a total of 200 patients from its 15 facilities present throughout the U.S. Moreover, patients enrolled by New York University/Bellevue will be the initial batch to enter the program. Also, after the collection of initial blood sample, the study would focus its resources on tracking patients’ progress for up to 12 months.

Patients from the study would be categorized at diagnosis into low-risk and high-risk cohorts using the company’s PredictSURE IBDTM biomarker. Apparently, PredictSURE IBDTM differentiates peoples based on the potential of suffering a serious disease course that would be categorized by the need for numerous escalations in therapy due to chronically active or frequently relapsing disease.

Speaking on the development, Paul Kinnon, CEO, PredictImmune, said that the company perceives this collaboration with Crohn’s & Colitis Foundation as a forward-looking step for both IBD and PredictImmune patients in the U.S.

Kinnon added that PredictImmune is thrilled to initiate the PRECIOUS trial, allowing them to extend its validation cohort and support the efficacy of the test in offering insights into the long-term course of the disease. Moreover, the study would propel both the firms one step closer to their vision of improving quality of life and disease outcomes for patients suffering from IBD.
 

Source Credit: https://www.predictimmune.com/predictimmune-and-the-crohns-colitis-foundation-announce-start-of-jointly-sponsored-study/

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

AstraZeneca’s COVID-19 vaccine manufacturing error clouds trial data
AstraZeneca’s COVID-19 vaccine manufacturing error clouds trial data
By Mateen Dalal

AstraZeneca and Oxford University have recently encountered a manufacturing error of their experimen...

Singapore Airlines raises $500M with the help of 10-year bonds
Singapore Airlines raises $500M with the help of 10-year bonds
By Mateen Dalal

SIA (Singapore Airlines), a flag carrier airline of the country of Singapore, has reportedly raised ...

New TMG 360 Media to optimize time to market for Healthtech companies
New TMG 360 Media to optimize time to market for Healthtech companies
By Mateen Dalal

TMG 360 Media, a novel digital platform created for driving brand awareness, strategic partnerships,...